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ABSTRACT
Background: The aim of this study was to ascertain the effect
of the extent and severity of bronchiectasis as determined
with high-resolution computed tomography (HRCT) on lung
function in patients with pure bronchiectasis, bronchiectasis
and asthma, and bronchiectasis and chronic obstructive pul-
monary disease (COPD).
Methods: One hundred nineteen patients (71 with pure
bronchiectasis, 25 asthmatic patients with bronchiectasis,
and 23 COPD patients with bronchiectasis) underwent HRCT
and pulmonary function tests. Computed tomography fea-
tures were scored by the consensus of 2 radiologists.
Results: There were no statistically significant differences
among the 3 patient groups regarding the extent of
bronchiectasis, bronchial dilatation degree, bronchial wall
thickening, decreased attenuation in the lung parenchyma, or
presence of mucus in the large and small airways. In the pure
bronchiectasis group, a negative correlation was found
between forced vital capacity (FVC) % of predicted, forced
expiratory volume in 1 sec (FEV1) % of predicted, the
FEV1/FVC ratio and the extent of bronchiectasis, bronchial
wall thickening, bronchial wall dilatation, and decreased
attenuation. At multivariate analysis the main morphologic
changes associated with impairment of FVC and FEV1 were
the extent of bronchiectasis and a decreased attenuation in
the lung parenchyma. The decrease in the FEV1/FVC ratio was
associated with bronchial wall dilatation. No correlation was
found between morphologic changes and indices of pul-
monary function in the asthma and COPD patients.
Conclusions: Morphologic changes associated with bronchi-
ectasis do not influence lung function in patients with asth-
ma and COPD directly, although they do play a role in impair-
ing pulmonary function in patients with bronchiectasis alone. 
Keywords: Asthma, bronchiectasis, computed tomography,
COPD, lung function tests, X-ray. 
RIASSUNTO 
Premessa: Scopo di questo studio era verificare l'effetto della
estensione e della gravità delle bronchiectasie, determinate
mediante tomografia computerizzata ad alta risoluzione
(HRCT), sulla funzionalità respiratoria nei pazienti con bron-
chiectasie semplici, bronchiectasie e asma, e con broncopneu-
mopatia cronica ostruttiva (BPCO) e bronchiectasie.
Metodi: 119 pazienti (71 pazienti con bronchiectasie semplici,
25 pazienti asmatici con bronchiectasie, e 23 pazienti con BP-
CO e bronchiectasie) sono stati sottoposti ad HRCT e prove di
funzionalità respiratoria. I punteggi delle HRCT sono stati at-
tribuiti sulla base di un consenso tra 2 radiologi.
Risultati: Non ci sono state differenze statisticamente signifi-
cative tra i 3 gruppi di pazienti riguardo all’estensione delle
bronchiectasie, al grado di dilatazione bronchiale, all’ispessi-
mento della parete bronchiale, alla riduzione di attenuazione
del parenchima polmonare, o alla presenza di muco nelle
grandi e piccole vie aeree. Nel gruppo con bronchiectasie
semplici, una correlazione negativa è stata trovata fra FVC (%
del teorico), FEV1 (% del teorico), rapporto FEV1/FVC ed
estensione delle bronchiectasie, ispessimento della parete
bronchiale, dilatazione della parete bronchiale e riduzione di
attenuazione. L'analisi multivariata ha mostrato che i cambia-
menti morfologici principali associati al deterioramento di
FVC e FEV1 sono l’estensione delle bronchiectasie e la riduzio-
ne di attenuazione nel parenchima polmonare. La diminuzio-
ne del rapporto FEV1/FVC è associata a dilatazione della pare-
te bronchiale. Nessuna correlazione è stata riscontrata tra le
variazioni morfologiche e gli indici respiratori nei pazienti con
asma e BPCO.
Conclusioni: Le modificazioni morfologiche associate a bron-
chiectasie non influenzano direttamente la funzionalità respi-
ratoria nei pazienti con asma e BPCO, ma hanno un ruolo nel
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deterioramento della funzionalità respiratoria nei pazienti
con bronchiectasie semplici.
Parole chiave: Asma, BPCO, bronchiectasie, raggi x, test di fun-
zionalità respiratoria, tomografia computerizzata.
INTRODUCTION
Bronchiectasis is defined as a permanent abnormal
dilatation of an airway [1]. Characteristically, most
patients with bronchiectasis have an obstructive
pulmonary function defect; however, those with
limited disease can maintain their pulmonary func-
tion, while those with diffuse and severe disease
can have restrictive or mixed impairment. The
mechanism of airway obstruction is not known with
certainty. Previous studies have found that it might
be associated with the collapse of large airways at
expiration [2], the retention of endobronchial secre-
tion [3], bronchial wall thickening [4], obliterative
bronchitis [5,6], or accompanying asthma [7].
Bronchiectasis can be diagnosed accurately with
high-resolution computed tomography (HRCT), and
morphologic changes caused by bronchiectasis can
be evaluated quantitatively. Previous studies have
shown that the degree of the morphologic changes
caused by bronchiectasis is associated with im-
paired pulmonary function [4,8-11].
Bronchiectasis, chronic obstructive pulmonary dis-
ease (COPD) and asthma are the diseases that cause
obstructive pulmonary functional impairment. In
patients with COPD it is seen radiologically in 2 to
29% of patients with asthma [12-14], and in 29 to
50% of patients with COPD [15-16]. Bronchiectasis
has been found to be associated with the clinical
severity of the disease in asthma patients [13-14]. 
In patients with COPD it has been shown to be as-
sociated with increased inflammatory airway mark-
ers, bacterial colonization, and severe  exacerba-
tions [16]. However, the relationship between the
morphologic changes associated with bronchiectasis
and the impairment in pulmonary function in patients
with asthma and COPD has not yet been clearly elu-
cidated.
In this retrospective study, we investigated the effect
of the extent and severity of bronchiectasis on lung
function of patients with asthma, COPD, and
bronchiectasis alone.
MATERIALS AND METHODS
The study included 119 consecutive clinically sta-
ble patients (54 males, 65 females) with bronchiec-
tasis confirmed by HRCT at our institution between
January 2004 and December 2007. Patients who
did not have PFTs within two months of the HRCT
were excluded. Patients younger than 18 years of
age and those with a history of lung resection, as
well as those with bronchial carcinoma, interstitial
lung disease, active tuberculosis, or lobar consoli-
dation on HRCT were also excluded. No patients
had allergic bronchopulmonary aspergillosis or cys-
tic fibrosis.
Patients were classified into 3 groups: those who
had only bronchiectasis (bronchiectasis group);
those with asthma and bronchiectasis (asthma
group); and those with COPD and bronchiectasis
(COPD group). The diagnosis of asthma was made
in accordance with the Global Strategy for Asthma
Management and Prevention (GINA) criteria [17]
and the diagnosis of COPD was made based on the
American Thoracic Society criteria [18]. The HRCT
results and pulmonary function parameters of the 3
groups were compared.
Lung function tests
Pulmonary function tests were performed using a
spirometer (Vmax 22, SensorMedics Corp., Yorba
Linda, CA, USA) in compliance with European
Respiratory Society standards. Forced vital capacity
(FVC) % of predicted, forced expiratory volume in 1
sec (FEV1) % of predicted, and the FEV1/FVC ratio
were measured and indicated as percentage values
in accordance with the age, sex and height of the
patients [19]. Airway obstruction was defined as an
FEV1/FVC value < 70%. 
High resolution computed tomography
Computed tomography images of the lungs were
obtained using a multidetector computed tomogra-
phy scanner (Sensation 4, Siemens, Erlangen,
Germany). Scanning parameters included a colli-
mation of 1.3 mm, section interval of 10 mm, 120
kVp, and 200 mAs. All images were obtained with
the patient in supine position at full inspiration and
without injection of a contrast medium. Scanned
images were reconstructed into a bone algorithm
through a 512 × 512 matrix with a small field of
view to image only pulmonary areas. Images were
obtained at a window width of 800 to 1500 H and
a window level of -500 to -700 H.
Radiologic evaluation
Computed tomography images were evaluated si-
multaneously by 2 radiologists (FT and UO) who
were blinded to patients’ data. The final decision
was made by consensus.
The extent of bronchiectasis, severity of bronchial
dilatation, bronchial wall thickness (BWT), the pres-
ence of mucus plugging in large and small airways,
and decrease in parenchymal attenuation (DA) were
scored for each lung lobe (the lingula was consid-
ered as a different lobe, making a total of 6 lobes)
separately, according to the modified Bhalla system
[20]. The scoring system was as follows: 1) extent of
bronchiectasis (0 = none, 1 = one or partial broncho -
pulmonary segment involved, 2 = two or more
bronchopulmonary segments involved, 3 = general-
ized cystic bronchiectasis); 2) severity of bronchial
dilatation (0 = normal, 1 = less than twice the diam-
eter of the adjacent pulmonary artery, 2 = more
than twice the diameter of adjacent pulmonary ar-
tery); 3) severity of bronchial wall thickening (0 =
normal, 1 = 0.5 × the diameter of the adjacent pul-
monary artery, 2 = 0.5 – 1.0 × the diameter of the






























0 of the adjacent pulmonary artery); 4) presence of
mucous plugging in large airways (0 = none, 1 =
present); 5) presence of mucous plugging in small
airways (0 = none, 1 = present); and 6) extent of de-
creased attenuation (0 = normal, 1 = ≤ 50% of lobar
volume, 2 = > 50% of lobar volume).
Statistical analyses
Data analyses were carried out using SPSS software
(Statistical Product and Services Solutions, version
11.5, SPSS Inc, Chicago, IL, USA). Depending on
the distribution, patient features, PFT parameters
and HRCT results, scores were expressed as means
plus standard deviation (SD) or medians with
ranges. Comparisons of pulmonary function test re-
sults among the groups and the differences in HRCT
scores were performed using independent sample t
test or the Mann-Whitney U test. Univariate analy-
ses of the associations between PFT results and
HRCT scores were determined using the Spearman
rank correlation. Stepwise forward regression analy-
sis was performed to identify which HRCT score in
the bronchiectasis group had an independent deter-
minant effect on pulmonary function. Values for p <
0.05 were accepted as statistically significant.
RESULTS
Patient characteristics
The characteristics of the patients in each of the 3
groups are summarized in Table I. While the mean
age of patients in the bronchiectasis and asthma
groups was not significantly different, it was higher
in the COPD group than in the other 2 groups 
(p < 0.05).
Computed tomography scores and lung function
test results
As shown in Table II, there were no statistically sig-
nificant differences in HRCT scores among the 3
groups. When PFT was evaluated, FVC% in the
bronchiectasis group was found to be higher than in
the asthma group. The predicted FEV1/FVC ratio was
higher in the bronchiectasis group than in the other
2 groups.
Correlation between lung function test results and
HRCT scores
In Table III, the relationships between the PFT re-
sults and HRCT scores are summarized for each of
the 3 groups. For the patients in the bronchiectasis
group, a strong negative correlation was found be-
tween the extent of bronchiectasis, the severity of
bronchial wall dilatation, BWT, the extent of DA,
and all functional parameter values (FVC%, FEV1%
and FEV1/FVC). There were no statistically signifi-
cant correlations between the HRCT scores and PFT
parameters in the asthma and COPD groups.
Multiple regression analyses
According to stepwise regression analysis (Table
IV), the extent of bronchiectasis and the DA score
were found to be positively related to impairment in
FVC% (both p < 0.05) and FEV1% (p < 0.001 and p
< 0.05, respectively). In addition, the bronchial di-
latation score was consistently associated with the
FEV1/FVC ratio (p < 0.001). 
DISCUSSION
To the best of our knowledge, this is the first study
to concomitantly determine a correlation between
the structural changes associated with bronchi -
ectasis and lung function impairment in patients
with pure bronchiectasis, as well as in patients with
asthma and COPD who have bronchiectasis. There
was no statistical difference between groups with
regard to structural change (the extent of bronchiec-
tasis, bronchial dilatation, BWT, DA in lung
parenchyma, and the presence of mucus plugging
in large and small airways) on HRCT.
Notwithstanding, while the HRCT scores of
bronchiectasis were found to be correlated with
pulmonary functional impairment only in patients
with pure bronchiectasis, morphologic changes as-
sociated with bronchiectasis were observed to be
not influential on pulmonary function in asthma
and COPD patients. 
We found a strong inverse correlation between the
extent of bronchiectasis, the degree of bronchial di-
latation, BWT, DA in lung parenchyma, and PFT pa-
rameters (FVC%, FEV1% and FEV1/FVC) in patients
with pure bronchiectasis. Conversely, the presence
of mucus plugging in airways (large and small) was
found to have less effect on PFT results; for instance,
mucus plugging in small airways correlated only
with the decrease in the FEV1/FVC ratio. Shah et al.
suggested that the presence of mucus plugging in
large and small airways in patients with cystic fibro-
TABLE I: CHARACTERISTICS OF PATIENTS    
Bronchiectasis Asthma COPD Total
N. (%) 71 (59.7) 25 (21) 23 (19.3) 119 (100)
Male/Female 31/40 2/23 21/2 54/65
Age, years
Mean ± SD 55.9 ± 13.8 55.4 ± 14.5 62.5 ± 6.8 57.0 ± 13.1
Max-Min 18-78 18-76 51-78 18-78
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sis did not affect pulmonary function [21]. In our
study, multivariate analyses revealed that the pres-
ence of mucus plugging in airways of patients with
bronchiectasis was not the primary cause of lung
function impairment. However, as stated by
Sheehan et al., when the mucus load of airways
varies over time this could be a reason for some
fluctuation in pulmonary function [9]. 
Multivariate analysis showed that the extent of
bronchiectasis and DA in the lung parenchyma
were the main determinants of the reduction of
both FVC% and FEV1%. These findings suggest that
the morphologic changes in patients with pure
bronchiectasis could lead both to restrictive and ob-
structive functional impairment. 
The increase in the extent of bronchiectasis reflects
the extension of inflammation and destruction in
airways, and thus a proportional impairment of pul-
monary function could be expected. The restrictive
component of impairment in lung function can be
explained by atelectasis, pleural disease, parenchy-
mal scarring, and peribronchial fibrosis that accom-
pany bronchiectasis.
The decrease of attenuation in the pulmonary
parenchyma that surrounds the bronchiectatic
bronchi implies an association of bronchiectasis
and obliterative bronchitis, and it can be seen as a
mosaic pattern radiologically. Reports have shown
that obliterative bronchitis that is accompanied by
bronchiectasis is one of the primary causes of the
obstructive type of pulmonary function impairment
[4,8,9]. It has been known since the 1960s that
when the small airways are obliterated due to
chronic infections and inflammation in
bronchiectatic large airways, the result is a contin-
ued collateral air flow through Khon pores instead
of a collapse in distal obstruction, with air trapping
emerging as a check-valve effect which is thought
to cause the decreased attenuation in the pul-
monary parenchyma [5]. Moreover, obliterative
bronchitis is considered by some authors to be a
part of bronchiectasis, and it is an early finding in
the pathogenesis of the disease. Hansell et al. con-
tend that monitoring the attenuation decrease in the
TABLE II: HRCT SCORES AND PULMONARY FUNCTION TEST (PFT) RESULTS FOR THE 3 GROUPS    
Bronchiectasis Asthma COPD Total
Extent of bronchiectasis* 5 (1-15) 4 (2-14) 5 (1-14) 5 (1-15)
Bronchial wall thickening* 2 (0-10) 2.5 (0-6) 2 (0-7) 2 (0-10)
Bronchial wall dilatation* 4 (1-16) 5 (1-15) 5 (1-15) 5 (1-16)
Plugging of large airways* 0 (0-5) 0 (0-5) 0 (0-2) 0 (0-5)
Plugging of small airways* 0 (0-5) 0 (0-3) 0 (0-2) 0 (0-5)
Decreased attenuation* 2 (0-9) 3 (0-9) 2 (0-9) 2 (0-9)
FVC% † 88.81 ± 22.02 76.32 ± 19.93 85.00 ± 17.58 85.45 ± 21.22
FEV1%,‡ 72.87 ± 25.74 51.96 ± 15.04 55.21 ± 13.38 65.06 ± 23.80
FEV1/FVC‡ 66.15 ± 13.04 56.64 ± 9.49 53.34 ± 11.76 61.68 ± 13.26
HRCT scores are medians with ranges. PFT results are means with SD. 
*No significant difference was found among the 3 groups (p > 0.05).
†p < 0.05 bronchiectasis group compared with asthma group; p = NS COPD group compared with asthma and bronchiectasis groups. 
‡p < 0.05 bronchiectasis group compared with asthma and COPD groups; p = NS asthma group compared with COPD group.
Definition of abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capa-
city; HRCT, high resolution computerized tomography.
TABLE III: UNIVARIATE CORRELATION BETWEEN PULMONARY FUNCTION TEST RESULTS AND HRCT SCORES    
FVC% pred. FEV1% pred. FEV1/FVC %
BRC Asthma COPD BRC Asthma COPD BRC Asthma COPD
Extent of bronchiectasis -0.472* -0.122 0.042 -0.570† -0.174 -0.388 0.524† -0.135 -0.137
Bronchial wall thickening -0.288† -0.064 0.062 -0.332† -0.040 -0.285 -0.296* -0.029 -0.147
Bronchial wall dilatation -0.449* -0.001 0.004 -0.562† -0.010 -0.075 0.532† -0.027 -0.163
Plugging of large airways -0.228 -0.195 0.113 -0.429† -0.285 0.298 0.432† -0.288 -0.311
Plugging of small airways -0.102 -0.081 0.264 -0.181 -0.054 0.092 -0.235* -0.020 -0.124
Decreased attenuation -0.392* -0.198 0.087 -0.517† -0.318 0.048 -0.353* -0.203 -0.069
Definition of abbreviations: BRC, bronchiectasis; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second;
FVC, forced vital capacity; HRCT, high-resolution computed tomography.

































pulmonary lobes, which have no sign of bronchiec-
tasis in patients with bronchiectasis, supports this
view [7]. On the assumption that the DA in the
parenchyma indirectly shows inflammation in the
lungs and the extent of destruction, as in our study,
the development of a mixed-type of pulmonary
functional defect can be expected when obliterative
bronchitis becomes widespread.
According to the multivariate analysis, in our pure
bronchiectatic patients the degree of bronchial di-
latation (p < 0.001) was the main independent vari-
able associated with a decrease of the FEV1/FVC ra-
tio. In the literature, contradictory results have been
obtained regarding the impact of the degree of
bronchial dilatation on pulmonary function in pa-
tients with bronchiectasis. Lee et al. [11] reported
that the degree of bronchial dilatation correlated
with airway obstruction, whereas Roberts et al. sug-
gested that the increase in the degree of bronchial
dilatation correlated with the amount of airway ob-
struction at lower levels [4]. Bronchial dilatation is
one of the main signs of bronchiectasis morpholog-
ically. It has been previously shown that small air-
way disease correlates with bronchial dilatation in
patients with bronchiectasis [22]. In parallel with
the increase of bronchial dilatation in the patients
with bronchiectasis, the increase in airway obstruc-
tion can be associated with morphologic changes in
small airways, which cannot be demonstrated radi-
ologically with HRCT. 
In the case of the coexistence of asthma and
bronchiectasis, it has been shown that bronchiectasis
can contribute to severe and difficult-to-control
asthma with pulmonary complications [13-14].
Lynch et al. noted that bronchial dilatation in asth-
matic patients did not influence pulmonary func-
tion; however, airway obstruction was seen to be
more severe in patients when emphysema was de-
tected [23]. Paganini et al. stated that the preva-
lence of irreversible structural changes such as
bronchiectasis, bronchial wall thickening, and em-
physema increased in patients with asthma, and
that these changes could be seen more frequently in
severely asthmatic patients [24]. Our study suggests
that the aggravating effect of bronchiectasis on asth-
ma is independent of the effect on pulmonary func-
tion. Impairment in the clearance of the bronchial
tree and the increase in epithelial permeability after
inflammation caused by bronchiectasis may result
in bacterial colonization and be the cause of more
severe and complicated asthma.
Similarly, there was no significant correlation be-
tween the morphologic changes caused by
bronchiectasis and pulmonary function in the
COPD group. The presence of bronchiectasis in pa-
tients with COPD caused bacterial colonization in
the lower respiratory tract, increased bronchial in-
flammation and, as a result, there were more severe
exacerbations [16]. While impairment in pul-
monary function was found to be correlated with
radiological extension of emphysema, the extent of
associated bronchiectasis and the degree of
bronchial dilatation did not affect airway obstruc-
tion [25]. Radiologically, it is difficult to differenti-
ate the hyperaeration of the lung caused by emphy-
sema from the decrease in attenuation in pul-
monary parenchyma associated with bronchiectasis
accompanied by obliterative bronchitis. Therefore,
a correlation between the decreased attenuation in
pulmonary parenchyma and pulmonary functions
may not be found in patients with COPD.
It is known that the morphologic changes detected
at HRCT in COPD, asthma and bronchiectasis arise
secondary to the airway remodelling process. These
morphologic changes have been defined mostly in
patients with only either asthma or COPD; for ex-
ample, the increase in BWT is characteristic of asth-
ma [26]. In our study, no difference was detected in
the morphologic changes of all 3 groups. The pres-
ence of bronchiectasis in our patients with asthma
or COPD might have formed a mixed-type inflam-
matory response resulting in the remodelling
process, leading to similar morphologic changes.
Further histopathologic studies are required to ex-
plain the pathogenesis of inflammatory and remod-
elling-related morphologic changes in patients with
more than one type of airway disease. On the other
hand, in our study, BWT was determined by a semi-
quantitative technique based on the diameter of the
pulmonary artery accompanying the bronchus.
TABLE IV: β COEFFICIENTS OF STEPWISE REGRESSION ANALYSIS FOR CORRELATION BETWEEN PULMONARY FUNCTION
RESULTS AND HRCT SCORES FOR THE PATIENTS WITH BRONCHIECTASIS ALONE    
FVC% pred. FEV1% pred. FEV1/FVC%
Extent of bronchiectasis -0.318 (0.016)* -0.450 (< 0.001)* -0.314 (0.055)
Bronchial wall thickening -0.041 (0.75) -0.053 (0.66) 0.043 (0.743)
Bronchial dilatation -0.061 (0.74) -0.286 (0.082) -0.620 (< 0.001)*
Plugging of large airways -0.029 (0.81) -0.209 (0.056) -0.102 (0.478)
Plugging of small airways -0.032 (0.76) -0.080 (0.409) -0.186 (0.052)
Decreased attenuation -0.264 (0.045)* -0.248 (0.038)* -0.127 (0.236)
Data in parentheses are p values.
*Statistically significant.
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Probably, if BWT were evaluated quantitatively, the
difference between groups could be interpreted
more clearly. Taking into consideration that hyper-
plasia of the pulmonary vasculature can develop in
patients with bronchiectasis, the relative thickening
of BWT occurring in each of the 3 diseases could be
expected. 
The functional changes that emerge as a conse-
quence of the interaction between COPD and asth-
ma with bronchiectasis may be related to causes
other than the morphologic changes arising from
bronchiectasis. In recent years, as a result of factor
analysis studies on asthma, COPD and bronchiectasis
patients, inflammatory, microbiologic, and function-
al parameters, as well as morphologic changes, have
been observed to affect the course and severity of
these diseases independently [27-28]. Therefore, it
has been emphasized that considering the different
parameters together is required while evaluating the
course of these diseases. In a study by Garcia et al.,
the extension of the disease, airway obstruction, dys-
pnea, and pulmonary hyperinflation in patients with
bronchiectasis were observed to be independent en-
tities affecting the clinical course of bronchiectasis
[28]. In the same study, the degree of dyspnea was
correlated more with pulmonary hyperinflation than
with airway obstruction. Therefore, the lack of a cor-
relation between functional parameters and mor-
phologic changes associated with bronchiectasis,
particularly in asthmatic and COPD patients, can be
considered not to be a contradictory result. The radi-
ologic findings and airway obstruction should be
considered as independent factors affecting the
severity of both diseases.
Our study has several limitations due to its retro-
spective nature. Firstly, the number of patients in the
asthma and COPD groups was relatively low.
However, we tried to select well defined patients
with asthma and COPD according to international
guidelines to allocate patients to three different
groups without overlapping. Increasing the number
of patients in the asthma and COPD groups would
have enhanced the power of our results. Secondly,
the HRCT evaluation was carried out by the con-
sensus of two radiologists rather than by independ-
ent observers. However, we believe that our radio-
logic findings were not affected significantly be-
cause the radiologists were blinded to the lung
function test results of the patients. Thirdly, the lack
of expiratory CT scans may have led to low sensitiv-
ity in detecting DA of the lung parenchyma. Finally,
total lung capacity (TLC) values were lacking in our
patients. Currently, the gold-standard diagnosis of
restrictive pulmonary impairment requires the
measurement of the TLC through helium dilution or
plethysmograph techniques. However, a low FVC
together with a normal or high FEV1/FVC ratio has
traditionally been accepted as a restrictive abnor-
mality and a low FVC with a low FEV1/FVC ratio as
a mixed-type abnormality [29]. 
In conclusion, our findings show that although the
morphologic changes associated with bronchiectasis
might be a determinant in impairing the pulmonary
function of patients with bronchiectasis alone, the
pulmonary function of patients with asthma and
COPD were not affected directly. Even though
bronchiectasis does not affect pulmonary function
in these patients, it might be considered as an inde-
pendent factor which plays a role in the clinical
course of asthma and COPD patients.
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